首页> 外文OA文献 >Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial

【2h】

Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial

机译：Empagliflozin单药治疗初治2型糖尿病患者的安全性，耐受性和对心血管代谢危险因素的影响：III期随机对照试验的双盲扩展

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者

展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-na?ve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial [J] . Michael Roden, Ludwig Merker, Anita Vedel Christiansen, Cardiovascular Diabetology . 2015,第1期

机译：初治型2型糖尿病患者使用恩帕格列净单药治疗的安全性，耐受性及对心血管代谢危险因素的影响：III期随机对照试验的双盲扩展
2. Long-term efficacy and safety of empagliflozin monotherapy in drug-na?ve patients with type 2 diabetes in Indian subgroup: Results from a 76-week extension trial of phase iii, double-blind, randomized study [J] . Sunil Gupta, Shehla Shaikh, Pooja Joshi, Indian Journal of Endocrinology and Metabolism . 2017,第2期

机译：恩帕格列净单药治疗印度亚组中未用过药物的2型糖尿病患者的长期疗效和安全性：一项为期7.6周的iii期，双盲，随机对照研究的结果
3. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension [J] . A. H. Barnett, S. Pate!, R. Harper, Diabetes, obesity & metabolism . 2012,第12期

机译：利格列汀单药治疗不适合二甲双胍的2型糖尿病患者：一项为期18周的随机，双盲，安慰剂对照的III期临床试验，并进行了34周的主动对照扩展
4. Randomised Controlled Trial of an In-Home Monitoring Intervention to Improve Health Outcomes for Type 2 Diabetes: Study Protocol [C] . Karen CARLISLE, Robin WARREN, Paul SCUFFHAM, Global Telehealth (Conference) . 2012

机译：随机对照试验的内部监测干预以改善2型糖尿病的健康结果：研究方案
5. Recruitment, retention and compliance in randomized, phase III clinical trials involving obese patients diagnosed with type 2 Diabetes Mellitus with respect to weight loss practicum report. [D] . Mithani, Moez S. 2012

机译：涉及诊断为2型糖尿病的肥胖患者的有关减肥实践的随机III期临床试验中的招募，保留和依从性报告。
6. Safety tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial [O] . Michael Roden, Ludwig Merker, Anita Vedel Christiansen, 2015

机译：Empagliflozin单药治疗初治2型糖尿病患者的安全性耐受性和对心血管代谢危险因素的影响：III期随机对照试验的双盲扩展
7. Long-term efficacy and safety of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes in Indian subgroup: Results from a 76-week extension trial of phase iii, double-blind, randomized study [O] . Sunil Gupta, Shehla Shaikh, Pooja Joshi, 2017

机译：印度亚组中2型糖尿病初治患者依巴利嗪单药治疗的长期疗效和安全性：第3阶段，双盲，随机研究的76周延长试验结果

Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial

著录项

引文网络

相似文献

相关主题

期刊订阅